DaVita (DVA)
(Delayed Data from NYSE)
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$150.30 USD
+0.34 (0.23%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $150.29 -0.01 (-0.01%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth C Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
6 Reasons Why Select Medical (SEM) Stock Looks Attractive
by Zacks Equity Research
Select Medical's (SEM) prolific lines of business, top-line growth, proven financial performance and strong cash flow, inorganic growth profile, partnerships with healthcare system giants bode well.
DaVita HealthCare (DVA) Down 4.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
DaVita HealthCare (DVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain DaVita (DVA) in Your Portfolio Now
by Zacks Equity Research
Investors' confidence is high on the DaVita (DVA) stock, thanks to solid prospects.
DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
DaVita's (DVA) bottomline in Q4 declines year over year.
New Strong Sell Stocks for February 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
DaVita HealthCare (DVA) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of -9.73% and -1.00%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Solid performance by net dialysis and the related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in the fourth quarter.
3 Outpatient Home Health Stocks Set to Ride the Industry's Upturn
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, rising dependence on telehealth and AI's dominant role should drive the Zacks Medical - Outpatient and Home Healthcare industry. DVA, CHE and USPH are well positioned to gain from the prospects.
NextGen's (NXGN) Platform Gets Adopted by FPA Women's Health
by Zacks Equity Research
FPA Women's Health utilizes NextGen's (NXGN) Virtual Visits, which are integral to the company's Patient Experience Platform
Why You Should Retain Veeva (VEEV) in Your Portfolio Now?
by Zacks Equity Research
Investor confidence/optimism is high on Veeva (VEEV) stock, driven by its solid prospects.
Here's Why You Should Add DaVita (DVA) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on DaVita (DVA) stock, driven by its solid prospects.
Is DaVita HealthCare (DVA) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
DVA vs. CHE: Which Stock Is the Better Value Option?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
Here's Why You Must Add Accuray (ARAY) to Your Portfolio Now
by Zacks Equity Research
Investor confidence is high on Accuray (ARAY) stock, courtesy of its solid prospects.
Align (ALGN) Rides on Robust Invisalign Sales Amid Coronavirus
by Zacks Equity Research
Align Technology's (ALGN) Invisalign clear aligner has been receiving positive feedback and holds huge long-term market potential.
CVS Health's (CVS) Front Store Sales Robust, LTC Suffers
by Zacks Equity Research
CVS Health's (CVS) Health Care Benefits arm benefits from strong Medicare annual enrollment period.
Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.
Quest Diagnostics (DGX) Ties Up With Hackensack Meridian Health
by Zacks Equity Research
Quest Diagnostics (DGX) collaborates with Hackensack Meridian Health to manage laboratory operation and provide high-quality healthcare network.
Select Medical (SEM) Rides on a Diversified Business Profile
by Zacks Equity Research
Select Medical's (SEM) supremacy in a fragmented market and its affordable healthcare services in each of its business segments bode well for the long haul.
Here's Why You Should Retain Allscripts (MDRX) Stock for Now
by Zacks Equity Research
Investor confidence is high on Allscripts (MDRX) stock on the back of its solid prospects.
New Strong Buy Stocks for December 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Medtronic (MDT) Gets Canada Nod for Micra AV to Treat AV Block
by Zacks Equity Research
With the approval, Medtronic (MDT) aims to strengthen its Cardiac and Vascular Group business globally.
Why You Should Retain Avanos Medical (AVNS) Stock for Now
by Zacks Equity Research
Investor confidence is high on Avanos Medical (AVNS), courtesy of solid prospects.
Varian (VAR) Inks Deal With Yonsei Cancer Center in Korea
by Zacks Equity Research
Varian (VAR) will be coordinating with Yonsei Cancer Center on formulating AI solutions, which are proven to upgrade early detection of cancer.
Here's Why You Should Hold onto Varian Medical (VAR) Stock Now
by Zacks Equity Research
Investor confidence is high on Varian Medical (VAR) stock, courtesy of solid prospects.